Thursday's U.S. Supreme Court decision barring gene patents isn't a disaster for Seattle's biotechnology industry.
The ruling still allows companies to patent synthetic DNA, which is most important for commercialization.
“I certainly don't think it's an innovation squasher,” said Andrew Serafini, an intellectual property lawyer specializing in life sciences. “I think the Supreme Court could have rendered a far more severe decision that really would have impacted the biotechnology industry…
Thursday's U.S. Supreme Court decision barring gene patents isn't a disaster for Seattle's biotechnology industry.
The ruling still allows companies to patent synthetic DNA, which is most important for commercialization.
“I certainly don't think it's an innovation squasher,” said Andrew Serafini, an intellectual property lawyer specializing in life sciences. “I think the Supreme Court could have rendered a far more severe decision that really would have impacted the biotechnology industry…